IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Deutsche Bank AG

IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer and rare diseases. The company's lead product candidate is IMGN632, an antibody-drug conjugate (ADC) targeting the programmed death ligand 1 (PD-L1) that is currently in clinical trials for the treatment of multiple myeloma.

Deutsche Bank AG is a multinational investment bank and financial services company headquartered in Frankfurt, Germany. The company operates in various segments, including corporate banking, investment banking, asset management, and post-trading.

According to IDEAYA's most recent disclosure with the SEC, Deutsche Bank AG increased its holdings in the company by 15.7% during the 3rd quarter of 2021. The institutional investor owned a total of 29,909 shares of the company's stock after acquiring an additional 4,054 shares during the quarter.

It is worth noting that IDEAYA Biosciences, Inc. has been experiencing significant growth in recent years, with its stock price increasing from around $12 per share in early 2020 to over $30 per share as of August 2021. This growth may have attracted the attention of institutional investors like Deutsche Bank AG, who are looking for promising investment opportunities in the biotechnology sector.

Overall, the increase in Deutsche Bank AG's holdings in IDEAYA Biosciences, Inc. is a positive sign for the company and its ongoing efforts to develop novel therapies for cancer and rare diseases.